Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures

Shannon W. Finks, Paul P. Dobesh, Toby C. Trujillo, George H. Crossley

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

As direct oral anticoagulants (DOACs) have demonstrated favorable efficacy and safety outcomes compared with vitamin K antagonists for the treatment and prevention of venous thromboembolism and the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, their role in the management of anticoagulation during electrophysiological procedures continues to evolve. At present, guidelines are limited regarding specific recommendations for the use of DOACs in these clinical settings. Here, we review available data regarding the risks and benefits associated with various periprocedural anticoagulation management approaches when patients receiving DOACs undergo electrophysiologic procedures including cardioversion, ablation, and device implantation. This discussion is intended to provide clinicians with an overview of available evidence and best practices to minimize the risk of both thromboembolic and bleeding events in the periprocedural setting.

Original languageEnglish (US)
Pages (from-to)245-254
Number of pages10
JournalCardiology in review
Volume26
Issue number5
DOIs
StatePublished - Sep 1 2018

Fingerprint

Electric Countershock
Anticoagulants
Vitamin K
Venous Thromboembolism
Embolism
Practice Guidelines
Atrial Fibrillation
Stroke
Guidelines
Hemorrhage
Safety
Equipment and Supplies
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures. / Finks, Shannon W.; Dobesh, Paul P.; Trujillo, Toby C.; Crossley, George H.

In: Cardiology in review, Vol. 26, No. 5, 01.09.2018, p. 245-254.

Research output: Contribution to journalReview article

@article{87f2d5e33f444eb8ab627d665eb3afa0,
title = "Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures",
abstract = "As direct oral anticoagulants (DOACs) have demonstrated favorable efficacy and safety outcomes compared with vitamin K antagonists for the treatment and prevention of venous thromboembolism and the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, their role in the management of anticoagulation during electrophysiological procedures continues to evolve. At present, guidelines are limited regarding specific recommendations for the use of DOACs in these clinical settings. Here, we review available data regarding the risks and benefits associated with various periprocedural anticoagulation management approaches when patients receiving DOACs undergo electrophysiologic procedures including cardioversion, ablation, and device implantation. This discussion is intended to provide clinicians with an overview of available evidence and best practices to minimize the risk of both thromboembolic and bleeding events in the periprocedural setting.",
author = "Finks, {Shannon W.} and Dobesh, {Paul P.} and Trujillo, {Toby C.} and Crossley, {George H.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1097/CRD.0000000000000188",
language = "English (US)",
volume = "26",
pages = "245--254",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures

AU - Finks, Shannon W.

AU - Dobesh, Paul P.

AU - Trujillo, Toby C.

AU - Crossley, George H.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - As direct oral anticoagulants (DOACs) have demonstrated favorable efficacy and safety outcomes compared with vitamin K antagonists for the treatment and prevention of venous thromboembolism and the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, their role in the management of anticoagulation during electrophysiological procedures continues to evolve. At present, guidelines are limited regarding specific recommendations for the use of DOACs in these clinical settings. Here, we review available data regarding the risks and benefits associated with various periprocedural anticoagulation management approaches when patients receiving DOACs undergo electrophysiologic procedures including cardioversion, ablation, and device implantation. This discussion is intended to provide clinicians with an overview of available evidence and best practices to minimize the risk of both thromboembolic and bleeding events in the periprocedural setting.

AB - As direct oral anticoagulants (DOACs) have demonstrated favorable efficacy and safety outcomes compared with vitamin K antagonists for the treatment and prevention of venous thromboembolism and the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, their role in the management of anticoagulation during electrophysiological procedures continues to evolve. At present, guidelines are limited regarding specific recommendations for the use of DOACs in these clinical settings. Here, we review available data regarding the risks and benefits associated with various periprocedural anticoagulation management approaches when patients receiving DOACs undergo electrophysiologic procedures including cardioversion, ablation, and device implantation. This discussion is intended to provide clinicians with an overview of available evidence and best practices to minimize the risk of both thromboembolic and bleeding events in the periprocedural setting.

UR - http://www.scopus.com/inward/record.url?scp=85056558431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056558431&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000188

DO - 10.1097/CRD.0000000000000188

M3 - Review article

C2 - 29621010

AN - SCOPUS:85056558431

VL - 26

SP - 245

EP - 254

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 5

ER -